NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. Show more

Location: Gooimeer 2-35, Naarden, 1411 DC, Netherlands | Website: https://www.newamsterdampharma.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

2.802B

52 Wk Range

$14.06 - $27.29

Previous Close

$24.88

Open

$24.90

Volume

613,978

Day Range

$24.43 - $25.73

Enterprise Value

2.063B

Cash

739.2M

Avg Qtr Burn

-31.03M

Insider Ownership

0.39%

Institutional Own.

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Obicetrapib + ezetimibe FDC Details Coronary plaque & inflammation	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Obicetrapib Details ASCVD (Cardiovascular Outcomes)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Obicetrapib + ezetimibe Details ASCVD and/or HeFH patients	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Obicetrapib Details ASCVD / HeFH (LDL-C efficacy)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Obicetrapib Details Heterozygous familial hypercholesterolemia (HeFH)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Obicetrapib + ezetimibe Details Type 2 diabetes and metabolic syndrome	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Obicetrapib Details Alzheimer's disease	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.